ALB and lung carcinoma: A review of nine clinical trials of non-targeted NPs in the treatment of lung cancer (seven using paclitaxel albumin-stabilized NPs, one using CRLX101, and one using ABI-009) concluded that these treatments were not inferior to the standard of care, with widely varying rates of serious adverse events [158].